Patents by Inventor Alison Mackinnon

Alison Mackinnon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20210221836
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: April 2, 2021
    Publication date: July 22, 2021
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil HENDERSON, Tariq SETHI, Alison MACKINNON, Hakon LEFFLER, Ulf NILSSON
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20190375776
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 12, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • IDIOPATHIC PULMONARY FIBROSIS-DETECTION, MONITORING, PREDICTION METHODS
    Publication number: 20170275326
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 28, 2017
    Applicant: GALECTO BIOTECH AB
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • Galactoside inhibitor of galectins
    Patent number: 9688713
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: June 27, 2017
    Assignee: Galecto Biotech AB
    Inventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
    Patent number: 9580456
    Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: February 28, 2017
    Assignee: Galecto Biotech AB
    Inventors: Ulf Nilsson, Hakon Leffler, Neil Henderson, Tariq Sethi, Alison MacKinnon
  • Novel galactoside inhibitor of galectins
    Publication number: 20160096861
    Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Applicant: GALECTO BIOTECH AB
    Inventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • Galactoside inhibitor of galectins
    Patent number: 9243021
    Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 26, 2016
    Assignee: Galecto Biotech AB
    Inventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • Galactoside Inhibitor of Galectin-3 and its use for Treating Pulmonary Fibrosis
    Publication number: 20150274764
    Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 1, 2015
    Applicant: Galecto Biotech AB
    Inventors: Ulf Nilsson, Hakon Leffler, Neil Henderson, Tariq Sethi, Alison MacKinnon
  • Novel Galactoside Inhibitor of Galectins
    Publication number: 20140121179
    Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson